Rank paroxetine, vortioxetine, and sertraline from easiest to hardest to discontinue.

Ranking by Ease of Discontinuation

From easiest to hardest to discontinue: vortioxetine, sertraline, paroxetine.

Rationale Based on Discontinuation Syndrome Risk

The ranking is primarily driven by the well-established risk profiles for discontinuation syndrome among these medications, with paroxetine being notably the most problematic.

Paroxetine (Hardest to Discontinue)

Paroxetine consistently demonstrates the highest risk of discontinuation syndrome among SSRIs 1. The AACAP guidelines explicitly state that discontinuation syndrome occurs "notably" with paroxetine, more so than other SSRIs 1. This is attributed to its:

• Short elimination half-life requiring more frequent dosing
• Potent serotonin reuptake inhibition with abrupt cessation effects
• Anticholinergic properties that compound withdrawal symptoms

The discontinuation syndrome manifests as dizziness, fatigue, lethargy, general malaise, myalgias, chills, headaches, nausea, vomiting, diarrhea, insomnia, imbalance, vertigo, sensory disturbances (particularly paresthesias/"electric shock sensations"), anxiety, irritability, and agitation 1.

Clinical practice guidelines recommend paroxetine should generally be avoided in older adults specifically because of higher rates of adverse effects, which includes discontinuation difficulties 2.

Sertraline (Moderate Difficulty)

Sertraline is associated with discontinuation syndrome, but to a lesser extent than paroxetine 1. The FDA label explicitly warns about discontinuation symptoms including dysphoric mood, irritability, agitation, dizziness, sensory disturbances (paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania 3.

Key considerations:

• Shorter half-life than fluoxetine but longer than paroxetine
• FDA labeling mandates: "A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible" 3
• While discontinuation symptoms occur, they are generally less severe and less frequent than with paroxetine
• Real-world data shows better persistence rates with sertraline compared to paroxetine (70.72% vs 72.66% discontinuation rates, p=0.0258) 4

Vortioxetine (Easiest to Discontinue)

Vortioxetine appears to have the most favorable discontinuation profile among these three medications. While specific discontinuation syndrome data is limited in the provided evidence, several factors support this ranking:

• Multimodal mechanism of action (not purely serotonergic) may reduce abrupt withdrawal effects
• No specific warnings about discontinuation syndrome in the comparative literature provided
• Recent network meta-analyses show vortioxetine has favorable acceptability profiles with lower all-cause discontinuation rates compared to placebo 5
• In head-to-head comparisons, vortioxetine demonstrated better tolerability than many other antidepressants 6

Clinical Implementation

When discontinuing any of these medications:

1. Always taper gradually - never stop abruptly
2. Paroxetine requires the slowest taper - consider switching to fluoxetine first (given its long half-life) before complete discontinuation in difficult cases
3. Monitor for 2-4 weeks post-discontinuation for emergence of withdrawal symptoms
4. If intolerable symptoms emerge, resume the previous dose and taper more slowly 3

Common Pitfall to Avoid

Do not assume all SSRIs have equivalent discontinuation profiles. The pharmacokinetic differences, particularly half-life and receptor binding profiles, create clinically significant variations in withdrawal symptom severity and duration.